Close Menu

NEW YORK (GenomeWeb) – Genome editing company Precision BioSciences today priced the initial public offering of its common stock, and is aiming to raise $126.4 million in gross proceeds from the sale.

The company priced 7.9 million shares of common stock at $16 per share, and is granting the underwriters a 30-day option to purchase approximately 1.2 million additional shares at the IPO price. The shares began trading on the Nasdaq Global Select Market under the ticker symbol DTIL today, and the offering is expected to close on April 1.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.